Anterix Reports FY26 Results; Contracted Proceeds Key to Thesis

What happened

Anterix reported full fiscal year 2026 results for the year ended March 31, 2026, as anticipated, likely confirming progress on its contracted proceeds backlog, which stood at $114m at Q2 FY26 with over $60m expected in the second half. However, underlying spectrum revenue remains minimal (only $1.6m in Q2 FY26), and recent net income has been driven by non-recurring gains from spectrum license exchanges and sales. Liquidity remains tight with $39m cash against ~$43m in known clearing and lease obligations, and no new large utility contracts were announced. The results underscore the slow conversion of pipeline to cash, keeping the risk of equity dilution alive if contract timing slips. Despite management's optimistic narrative, the core business has not yet achieved sustainable, recurring revenue generation.

Implication

For investors, the FY26 results provide a checkpoint on Anterix's ability to convert its backlog into cash, but they do not alter the fundamental risk profile. While the company likely met its guidance of over $60m in second-half receipts, core spectrum revenue remains negligible, and profitability still hinges on non-recurring gains. Without a clear signal of new large utility contracts (e.g., $50M+) or tangible TowerX/CatalyX revenue, the stock is likely to remain range-bound near current levels. The attractive entry remains around $18, while the current price near $24 offers limited upside without further de-risking. Investors should wait for either validated contract wins or clear solutions traction before increasing exposure.

Thesis delta

The FY26 results reinforce the existing thesis: Anterix is making steady but slow progress on contracted proceeds, but the core investment case remains unchanged. No material shift in the risk-reward balance, as the company still needs to demonstrate scalable recurring revenue and avoid dilution. The WAIT rating remains appropriate.